These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32555120)

  • 1. Lasmiditan (Reyvow) and ubrogepant (Ubrelvy) for acute treatment of migraine.
    Med Lett Drugs Ther; 2020 Mar; 62(1593):35-39. PubMed ID: 32555120
    [No Abstract]   [Full Text] [Related]  

  • 2. Drugs for migraine.
    Med Lett Drugs Ther; 2023 Jun; 65(1678):89-96. PubMed ID: 37266987
    [No Abstract]   [Full Text] [Related]  

  • 3. Drugs for Migraine.
    Med Lett Drugs Ther; 2020 Oct; 62(1608):153-160. PubMed ID: 33434187
    [No Abstract]   [Full Text] [Related]  

  • 4. Rimegepant (Nurtec ODT) for acute treatment of migraine.
    Med Lett Drugs Ther; 2020 May; 62(1597):70-72. PubMed ID: 32555113
    [No Abstract]   [Full Text] [Related]  

  • 5. Atogepant (Qulipta) for migraine prevention.
    Med Lett Drugs Ther; 2021 Nov; 63(1636):169-171. PubMed ID: 35085204
    [No Abstract]   [Full Text] [Related]  

  • 6. Zavegepant (Zavzpret) for acute treatment of migraine.
    Med Lett Drugs Ther; 2023 Jul; 65(1681):116-118. PubMed ID: 37460143
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison table: Triptans.
    Med Lett Drugs Ther; 2023 Jun; 65(1678):e97-e99. PubMed ID: 37266988
    [No Abstract]   [Full Text] [Related]  

  • 8. Lasmiditan for the acute treatment of migraine.
    Tepper D
    Headache; 2020 Jun; 60(6):1225-1226. PubMed ID: 32474924
    [No Abstract]   [Full Text] [Related]  

  • 9. A new dihydroergotamine nasal spray (Trudhesa) for migraine.
    Med Lett Drugs Ther; 2021 Dec; 63(1640):204-207. PubMed ID: 35100240
    [No Abstract]   [Full Text] [Related]  

  • 10. Lasmiditan for Acute Treatment of Migraine in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Yang Y; Sun Y; Gao B; Wang Z; Chen Z; Wang Z
    CNS Drugs; 2020 Oct; 34(10):1015-1024. PubMed ID: 32857291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
    Jakate A; Blumenfeld AM; Boinpally R; Butler M; Borbridge L; Contreras-De Lama J; McGeeney D; Periclou A; Lipton RB
    Headache; 2021 Apr; 61(4):642-652. PubMed ID: 33818780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings.
    Polavieja P; Belger M; Venkata SK; Wilhelm S; Johansson E
    J Headache Pain; 2022 Jul; 23(1):76. PubMed ID: 35790906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs.
    Tfelt-Hansen PC; Pihl T; Hougaard A; Mitsikostas DD
    Expert Opin Investig Drugs; 2014 Mar; 23(3):375-85. PubMed ID: 24289494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis.
    Johnston K; Popoff E; Deighton A; Dabirvaziri P; Harris L; Thiry A; Croop R; Coric V; L'Italien G; Moren J
    Expert Rev Pharmacoecon Outcomes Res; 2022 Jan; 22(1):155-166. PubMed ID: 34148501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN.
    Krege JH; Rizzoli PB; Liffick E; Doty EG; Dowsett SA; Wang J; Buchanan AS
    Cephalalgia; 2019 Jul; 39(8):957-966. PubMed ID: 31166697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Dizziness After Lasmiditan Usage: Findings From the SAMURAI and SPARTAN Acute Migraine Treatment Randomized Trials.
    Tepper SJ; Krege JH; Lombard L; Asafu-Adjei JK; Dowsett SA; Raskin J; Buchanan AS; Friedman DI
    Headache; 2019 Jul; 59(7):1052-1062. PubMed ID: 31152441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecule of the month. Lasmiditan hydrochloride.
    Drug News Perspect; 2010 Sep; 23(7):455. PubMed ID: 20862397
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN).
    Loo LS; Plato BM; Turner IM; Case MG; Raskin J; Dowsett SA; Krege JH
    BMC Neurol; 2019 Aug; 19(1):191. PubMed ID: 31409292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lasmiditan: First Approval.
    Lamb YN
    Drugs; 2019 Dec; 79(18):1989-1996. PubMed ID: 31749059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study).
    Brandes JL; Klise S; Krege JH; Case M; Khanna R; Vasudeva R; Raskin J; Pearlman EM; Kudrow D
    Cephalalgia; 2019 Oct; 39(11):1343-1357. PubMed ID: 31433669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.